Table 1

Evidence for involvement of Rho in GPCR-mediated responses

	Actin Cytoskeletal Rearrangement	FAK Phosphorylation	Cell Migration and Adhesion	Growth and Gene Expression	Contraction/MLC Phosphorylation	Rho Activation
LPA	Ridley, 1992 Jalink, 1994 Tigyi, 1996b Vexler, 1996	Kumagai, 1993 Ridley, 1994	Yoshioka, 1998	Hill, 1995b Mao, 1998	Chrzanowska-Wodnicka, 1996	Fleming, 1996 Aoki, 1998 Gohla, 1998
Thrombin	Jalink, 1994 Majumdar, 1998		Seasholtz, 1999	Majumdar, 1998 Mao, 1998 Seasholtz, 1999	Essler, 1998 Majumdar, 1998	Donovan, 1997 Seasholtz, 1999
PGE₂	Katoh, 1996
Endothelin	Koyama, 1996	Rankin, 1994 Cazaubon, 1997		Cazaubon, 1997 Kim, 1997	Croxton, 1998	Fleming, 1996
Bombesin	Ridley, 1992	Rankin, 1994				Aoki, 1998
FMLP^1-a			Laudanna, 1996			Laudanna, 1996, 1997
Sphingolipids	Sufferlein, 1995 Postma, 1996	Sufferlein, 1995 Wang F, 1997
Angiotensin				Aoki, 1998		Aoki, 1998
α Adrenergic				Sah, 1996 Thorburn, 1997 Hoshijima, 1998	Kokuba, 1995	Gong, 1997 Betuing, 1998
Muscarinic	Togashi, 1998			Fromm, 1997	Croxton, 1998 Kai, 1998	Keller, 1997

Selected or representative publications documenting involvement of Rho in various cellular effects of GPCR agonists are referenced above by the first author’s last name and date. The complete list of authors and titles can be found in the reference section.
↵1-a FMLP, formyl-methionyl-leucyl-phenylalanine.